Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013980 | 0.86 | COMT (0.33) | EPAS1TDP1VCAM1SMN1; SMN2 | |
| SCHEMBL2013349 | 0.79 | HSD11B1 (0.35) | — | |
| SCHEMBL2016557 | 0.79 | COMT (0.39) | TDP1MAPTSMN1; SMN2 | |
| SCHEMBL2014632 | 0.75 | EPAS1 (0.32) | EPAS1TDP1SMN1; SMN2 | |
| SCHEMBL2014020 | 0.72 | MEN1 (0.35) | TDP1MAPTSMN1; SMN2 | |
| SCHEMBL29741252 | 0.72 | ALDH1A1 (0.38) | EPAS1MAPT | |
| SCHEMBL15621478 | 0.72 | ALDH1A1 (0.38) | EPAS1MAPT | |
| SCHEMBL2034810 | 0.71 | HSD11B1 (0.37) | TDP1 | |
| SCHEMBL8268186 | 0.69 | VCAM1 (0.41) | EPAS1TDP1VCAM1SMN1; SMN2 | |
| SCHEMBL2393802 | 0.69 | POLB (0.39) | VCAM1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108984-B2 | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108984-B2 | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108984-B2 | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2012125629-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125629-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | EPAS1 1893/4885P2RY6 1583/4885TDP1 2910/4885 |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PDPK1, PIK3CD | EPAS1 830/4885P2RY6 167/4885TDP1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.